Research programme: anticancer monoclonal antibodies and protein therapeutics - Fusion Antibodies
Alternative Names: Fsn 0306; Fsn 0503; Fsn 0503h; Fsn 1006; Fsn 1103; Fsn 1107Latest Information Update: 04 Nov 2017
At a glance
- Originator Fusion Antibodies
- Class Monoclonal antibodies; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors; Cathepsin S inhibitors; Cysteine endopeptidase inhibitors; Heparin-binding EGF-like growth factor inhibitors; MDK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer; Solid tumours
- Discontinued Multiple myeloma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Ireland (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Ireland (Parenteral)
- 02 Aug 2013 Fsn 1006 is available for licensing as of 09 Nov 2012. http://fusionantibodies.com/